〔Abstract〕 Objective To investigate the effects of different calcalitriol administration Methods on intact parathyroid hormone (iPTH) and calcium and phosphorus metabolism in patients with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD). Methods A total of 86 SHPT patients who were admitted to Shangqiu First People's Hospital from September 2019 to December 2020 and treated with MHD were randomly divided into a control group (43 cases, treated with continuous low-dose calcitriol) and an observation group (43 cases, treated with intermittent high-dose calcitriol). The treatment time was divided into before treatment (T0), 1 month after treatment (T1), 2 months after treatment (T2), 3 months after treatment (T3), 4 months after treatment (T4), 5 months after treatment (T5) and 6 months after treatment (T6); iPTH, blood calcium and blood phosphorus levels were compared between the two groups at each time period, and the incidence of adverse drug reactions during treatment period was compared between the two groups. Results The iPTH levels in both groups from T1 to T6 were decreased compared with those at T0, and the differences were statistically significant (P < 0.05). There was no significant difference in iPTH levels between the the two groups at the same time from T1 to T6 (P > 0.05). From T1 to T4, blood calcium and phosphorus levels in the two groups were compared with those at T0, with no statistical significance (P > 0.05). From T5 to T6, serum calcium and phosphorus levels in the control group were significantly higher than those at T0, with statistical significances (P < 0.05). From T5 to T6, there was no statistical significance in serum calcium and phosphorus levels in the observation group compared with T0 (P > 0.05). From T5 to T6, serum calcium and phosphorus levels in the control group were significantly higher than those in the observation group, the differences were statistically significant (P < 0.05). The total incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Intermittent high_x005fdose calcitriol administration for SHPT patients receiving MHD treatment is more beneficial to control calcium and phosphorus metabolism level and prevent the occurrence of high calcium and phosphorus, compared with continuous low-dose administration, with better medication safety.